A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial — IMPROVE-HCM

Non-obstructive Hypertrophic Cardiomyopathy Clinical Trial

Official title:
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy

Status Completed

Clinical Trial Summary

The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cardiomyopathies
Cardiomyopathy, Hypertrophic
Hypertrophy
Non-obstructive Hypertrophic Cardiomyopathy

Clinical Trial Details

NCT number	NCT04826185
Study type	Interventional
Source	Imbria Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	June 14, 2021
Completion date	September 18, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03723655` - A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM	Phase 2/Phase 3
Completed	`NCT03442764` - A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)	Phase 2
Completed	`NCT01631006` - Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy	N/A
Recruiting	`NCT05569382` - Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy	Phase 4